The effect of tocilizumab on cytokine release syndrome in COVID-19 patients

BACKGROUND: This study was aimed to assess the efficacy and safety of tocilizumab (TCZ) and to investigate the factors related to the progress and mortality of patients with a secondary cytokine release syndrome caused by SARS-CoV-2. METHODS: A retrospective descriptive observational study of hospit...

Descripción completa

Detalles Bibliográficos
Autores principales: de Cáceres, Carmen, Martínez, Rodrigo, Bachiller, Pablo, Marín, Laura, García, José Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650573/
https://www.ncbi.nlm.nih.gov/pubmed/33165762
http://dx.doi.org/10.1007/s43440-020-00186-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650573/
https://www.ncbi.nlm.nih.gov/pubmed/33165762
http://dx.doi.org/10.1007/s43440-020-00186-z

Ejemplares similares